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Dysregulation of metabolic 
pathways by carnitine 
palmitoyl‑transferase 1 plays a key 
role in central nervous system 
disorders: experimental evidence 
based on animal models
Michael Sloth trabjerg1, Anne Skøttrup Mørkholt1, Jacek Lichota1, 
Michal Krystian Egelund Oklinski1, Dennis christian Andersen1, Katrine Jønsson3, 
Kasper Mørk1, Marie‑Louise Nibelius Skjønnemand1, Lona John Kroese2, 
colin eliot Jason pritchard2, ivo Johan Huijbers2, parisa Gazerani1, Angelique corthals4 & 
John Dirk Vestergaard Nieland1*
The etiology of CNS diseases including multiple sclerosis, Parkinson’s disease and amyotrophic lateral 
sclerosis remains elusive despite decades of research resulting in treatments with only symptomatic 
effects. In this study, we provide evidence that a metabolic shift from glucose to lipid is a key 
mechanism in neurodegeneration. We show that, by downregulating the metabolism of lipids through 
the key molecule carnitine palmitoyl transferase 1 (CPT1), it is possible to reverse or slowdown disease 
progression in experimental models of autoimmune encephalomyelitis‑,  SOD1G93A and rotenone 
models, mimicking these CNS diseases in humans. The effect was seen both when applying a CPT1 
blocker or by using a Cpt1a P479L mutant mouse strain. Furthermore, we show that diet, epigenetics, 
and microbiota are key elements in this metabolic shift. Finally, we present a systemic model for 
understanding the complex etiology of neurodegeneration and how different regulatory systems 
are interconnected through a central metabolic pathway that becomes deregulated under specific 
conditions.
In the last decades, the incidence of central nervous system (CNS) diseases including multiple sclerosis (MS), 
amyotrophic lateral sclerosis (ALS), and Parkinson’s Disease (PD) have been  increasing1–3. CNS diseases, specifi-
cally neurodegenerative diseases, have a pronounced impact on the patient’s quality of life and represent a major 
economic and emotional burden to both close relatives and society at large. The etiology and pathogenesis of 
CNS diseases remain elusive. Consequently, few treatment options exist, and no cure is yet available for those 
aforementioned CNS disorders. Treatments are mainly limited to partial symptomatic relief, but progression 
and the long-term outcome often remain unimproved.
Though seemingly individual conditions, several CNS diseases share common etiological and pathological 
pathways involved in onset and progression such as inflammation, oxidative stress, demyelination, dysbiosis 
in the gut and changes in  metabolism1,3–5. Moreover, we know that increased levels of low-density lipoprotein 
cholesterol (LDL), triglycerides and total cholesterol levels, and decreased levels of high-density lipoprotein 
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(HDL) cholesterol are also associated with disease  progression6–8. Thus, we propose a novel perspective for 
looking at MS, ALS and PD pathogenesis through a systemic perspective with focus on the role of dysregulated 
metabolism in these conditions. In MS, several mechanisms of immunoreactivity have been proposed such as 
molecular mimicry, bystander activation, and altered peptide  ligand1. However, studies indicate that upregulated 
lipid metabolism, and changes in the lipid binding protein of myelin could be the trigger of disease leading to 
the activation, and ultimately dysregulation, of the immune  system9–11. The activation of immune cells such as 
microglia, can lead to the production of reactive oxygen species, and thereby oxidative  stress12,13. Moreover, a 
shift to lipid metabolism has been found to drive activity of immune cells and  inflammation14,15. In PD, several 
mechanisms leading to neurodegeneration such as mitochondrial dysfunction, and oxidative stress are linked to 
the metabolism of  lipids16. Furthermore, PD patients have lower serum levels of lipids, which indicates a potential 
role of metabolic alterations in disease onset, since a higher level of lipids in serum has been found associated 
with a low prevalence of  PD6. In ALS, various disease mechanisms causing irreversible damage to motor neurons 
such as endoplasmic reticulum stress, inflammation, oxidative stress, mitochondrial dysfunction and glutamate 
excitotoxicity have also been  suggested17. A higher level of triglycerides have been associated with longer survival 
rates in ALS  patients18. In accordance, ALS-mouse models revealed that a decrease in lipids level could lead to 
disease progression and that lipid metabolism is upregulated prior to  disease8,19,20. Based on this evidence, our 
approach is to investigate neurodegenerative, pathological changes in lipid metabolism using in vivo models 
of MS, ALS, and PD. Specifically, we aimed at investigating the role of a key mitochondrial molecule, carnitine 
palmitoyl transferase 1 (CPT1), involved in the regulation of both lipids and glucose, and how its activity in the 
CNS could impact disease development and progression.
To maintain the homeostasis of energy in the brain, a balance between the oxidation of glucose and that of 
fatty acids is  required21. Fatty acid oxidation occurs through the uptake of long-chain fatty acids (LCFA), facili-
tated by fatty acid transport proteins (FATPs)22. Following the uptake, LCFA are converted to acyl-CoA by the 
acyl-CoA synthase activity of the  FATPs21. Due to the impermeability of the outer mitochondrial membrane to 
fatty acyl-CoA, a carnitine shuttle, CPT1, is needed to convert acyl-CoA into acyl-carnitine. This is followed by 
the second step within the inner mitochondrial membrane, where CPT2 reconverts acyl-carnitine into acyl-CoA 
and  carnitine21. This underpins the clear-cut function of the mitochondria, and specifically CPT1 and CPT2, to 
permit β-oxidation of fatty acids, which is necessary for the production of acetyl-CoA used in ATP production 
by the Krebs  cycle21,23.
Energy metabolism is crucial to cell and organ function, but metabolic pathways have often been overlooked 
in studies relating to CNS injuries and diseases. We designed a series of experiments to understand how dysfunc-
tions in metabolic pathways are involved in the progression, etiology, and onset of neurodegeneration with a 
focus on MS, ALS, and PD. Here, we present evidence of common pathogeneses and consequently provide a tar-
get to act on disease modifying mechanisms in addition to control of symptoms. We hypothesize that metabolic 
dysregulation is the basis for development and progression of several CNS diseases, specifically those leading to 
neurodegeneration. Specifically, we propose that the dysregulation is—to some degree—a consequence of a shift 
from glucose to lipid metabolism, which affects several pathways involved in the etiology and progression of 
CNS diseases. This metabolic shift can be a consequence of several factors: genetic predisposition, environmental 
factors or most likely, a combination of both. In this study, we have tested our hypothesis by pharmacologically 
blocking CPT1 with the antagonist, etomoxir, and genetically by producing a rodent model with a Cpt1a muta-
tion. The mutation mimics a known human mutation found in the Inuit population, shown to lower the efficiency 
of CPT1A from 100 to 22%. This study provides further evidence on the role of metabolic alterations and the 
effect of targeting CPT1 in MS, ALS, and PD through in vivo studies.
Figure 1.  The efficacy of pharmacological and genetic inhibition of CPT1 in EAE models of MS. (a) 
Experimental setup for the EAE-etomoxir study in female C57Bl/6J mice. (b) Disease score of WT-EAE-E 
(n = 7) and WT-EAE (n = 5) mice. (c) Body weight of WT-EAE-E (n = 7) and WT-EAE (n = 5) mice. (d) Mean 
fold gene expression change of IL-17α in FB, MB and HB of WT-EAE (n = 5) and Cpt1a-EAE (n = 6) mice at 
day 24. (e) Mean fold gene expression change of Nrf2 and Ho-1 in FB, MB and HB of WT-EAE-E (n = 7) and 
WT-EAE-P (n = 5) mice at day 24. (f) Cytokine level of IL-6 and TNF-α in serum of WT-EAE-E (n = 3) and 
WT-EAE-P (n = 3) mice at day 24. (g) Experimental setup for the Cpt1a-EAE study comparing Cpt1a-mutant 
mice with C57Bl/6J female mice. (h) Disease score of WT-EAE (n = 5) and Cpt1a-EAE (n = 6) mice from day 
10. (i) Body weight of WT-EAE (n = 5) and Cpt1a-EAE (n = 6) mice from day 10. (j) Mean fold gene expression 
change of Nrf2 and Ho-1 in FB, MB and HB of WT-EAE (n = 5) and Cpt1a-EAE (n = 6) mice at day 24. (k) Mean 
fold gene expression change Nox-2 and Pgc1α1 in FB, MB and HB of WT-EAE-E (n = 7) and WT-EAE-P (n = 5) 
mice at day 24. (l) Mean fold gene expression change of Nox-2 and Pgc1α1 in FB, MB and HB of WT-EAE (n = 5) 
and Cpt1a-EAE (n = 6) mice at day 24. (m) Cytokine level of IL-6 and TNF-α in serum of WT-EAE (n = 3) and 
Cpt1a-EAE (n = 4) mice at day 24. Asterisks indicate the level of statistical significance (*p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001). Abbreviations: Cpt1a, carnitine palmitoyl transferase 1a with a p479l mutation; E, 
etomoxir; EAE, experimental autoimmune encephalomyelitis; WT, wild type; FB, forebrain; MB, midbrain; HB, 
hindbrain; MOG, Myelin-oligodendrocyte  glycoprotein35–55  (MOG35–55), CFA, Complete Freund’s Adjuvant; S.c., 
Subcutaneous; I.p., Intraperitoneal; Inj., Injection; SEM: standard error of the mean. We acknowledge Servier 
Medical Art for the mouse illustration, which can be found at: https ://smart .servi er.com/ with the following 
license; https ://creat iveco mmons .org/licen ses/by/3.0/. No changes were made to the drawing.
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Results
Pharmacological and genetic inhibition of CPT1 ameliorates experimental autoimmune 
encephalomyelitis induction and symptoms. An increased expression of CPT1A has been demon-
strated in MS patients and EAE  models24,25. Consequently, the effect of pharmacological inhibition of CPT1 
by etomoxir was evaluated in the experimental autoimmune encephalomyelitis (EAE) animal model of MS 
(Fig. 1a). Myelin-oligodendrocyte  glycoprotein35–55  (MOG35–55) immunized C57bl/6J female mice receiving eto-
moxir (WT-EAE + E) (n = 7) showed a significant decreased mean clinical score compared to the mice receiving 
placebo treatment (WT-EAE + P) (n = 5) (Fig. 1b) and no decrease in body weight (Fig. 1c). Following the animal 
experiments, we conducted RT-qPCR to evaluate whether etomoxir changed the gene expression of markers 
of oxidative stress and mitochondrial function in the fore-, mid-, and hindbrain. Interestingly, we found that 
etomoxir-treated mice had a tendency towards lower gene expression of Ho-1 and Nox-2 in the brain (Fig. 1d,e), 
although it did not reach statistical significance. However, etomoxir-treated mice had statistical higher expres-
sion of Pgc1α (Fig. 1e) in the forebrain, indicating amelioration of mitochondrial dysfunction at least in some 
parts of the brain. To evaluate whether etomoxir treatment had affected the inflammatory response, we evalu-
ated serum levels of IL-6 and TNF-α and found that etomoxir-treated mice had significantly lower levels of both 
cytokines (Fig. 1f). This indicates that downregulation of CPT1 lipid metabolism affects several key processes in 
the disease progression of EAE.
To further assess the contribution of CPT1A in the development of EAE, we generated Cpt1a-mutated  mice26 
and compared these with WT mice. Both WT-EAE (n = 5) and Cpt1a-EAE (n = 6) female mice were immunized 
with  MOG35–55 (Fig. 1g). The results showed that the WT-EAE mice presented worsening of mean clinical scores 
of up to 4, compared to the Cpt1a-EAE mice with a mean clinical score of 0.5. The difference between the two 
groups was statistically significant from day 14 of the experiment and onwards (Fig. 1h). The body weight was also 
used as a hallmark to evaluate the effect of EAE immunization. The body weight in the group of WT-EAE mice 
(n = 5) decreased from day 10 to day 24, and was significantly different from the body weight of the Cpt1a-EAE 
mice (n = 6) at the last day of the experiment (Fig. 1i). Based on the clinical effects, we evaluated whether the 
Cpt1a-mutation changed gene expression of markers of oxidative stress, mitochondrial function, and inflamma-
tion in the fore-, mid-, and hindbrain of both WT-EAE and Cpt1a-EAE mice. The Cpt1a-EAE group had lower 
expression of Ho-1, and significantly lower expression of Nox-2 in the hindbrain (Fig. 1j–k). This indicated that 
the Cpt1a mutation affected oxidative stress. Moreover, the Cpt1a-EAE group had significantly higher expres-
sion of Pcg1α in the hindbrain (Fig. 1k) indicating that the downregulation of CPT1A lipid metabolism resulted 
in amelioration of mitochondrial dysfunction. The Cpt1a-EAE group had significantly lower IL-17α expression 
in the mid-, and hindbrain (Fig. 1l). This was consistent with lower serum levels of IL-6 and TNF- α in serum 
compared to WT-EAE mice (Fig. 1m). This indicated that downregulation of CPT1A activity was able to dimin-
ish inflammation.
Cpt1a mutation provides resistance to high fat diet accelerated eAe induction and symp-
toms. The Cpt1a-mutated mouse model resembles the human CPT1A mutation found in the Inuit popula-
tion living in Canada and Greenland. The CPT1A nucleotide mutation located at position 1436 C > T predicting 
a substitution of proline to leucine at codon 479 (P479L)27 resulting in a residual activity of 22% of the CPT1A 
 protein28. In accordance with this, we have found that Cpt1a-mutated mice have changes in glucose, LDL and 
HDL levels (Fig. 2a–d) and that Cpt1a-mutated mice have decreased Cpt1a expression in the spinal cord (Fig. 2e). 
High-fat diet (HFD) is associated with increased disease severity of both MS and EAE by changes in metabolism, 
inflammation and oxidative  stress26. Specifically HFD has been found to upregulate CPT1A lipid  metabolism29. 
Therefore, we investigated the effect of HFD in the EAE model using female Cpt1a and WT mice (Fig. 2f). The 
results showed that the mean clinical scores of the WT-EAE + HFD female mice (n = 5) increased significantly 
from day 10, at which the mice were subjected to the HFD, until day 24. Additionally, the mean clinical scores 
were significantly lower for the Cpt1a-EAE + HFD mice (n = 6) at day 24 compared to WT-EAE + HFD (Fig. 2g). 
Interestingly, we have found that female WT mice receiving HFD for 10 weeks have decreased expression of Nrf2 
and Pgc1α in the spinal cord compared to WT + ND mice (Fig. 2h–i). The data of low disease induction in the 
Figure 2.  Cpt1a-mutated mice have changes in serum metabolites and high fat diet affects disease progression 
in EAE mouse model, and gene expression in spinal cord. (a) Glucose level in serum from Cpt1a-mutated male 
mice (n = 12) and WT mice (n = 15). (b) LDL level in serum from Cpt1a-mutated male mice (n = 6) and WT 
mice (n = 5). (c) HDL level in serum from Cpt1a-mutated male mice (n = 6) and WT mice (n = 5). (d) LDL/
HDL ratio in serum from Cpt1a-mutated male mice (n = 6) and WT mice (n = 5). (e) Mean fold gene expression 
change of Cpt1a in spinal cord of female WT- (n = 3) and Cpt1a-mutated mice (n = 3). (f) Experimental setup 
for the high fat diet Cpt1a-EAE and WT-EAE study comparing the effect of HFD on EAE disease progression. 
(g) Efficacy of high-fat diet on EAE disease severity of WT-EAE (n = 5) and Cpt1a-EAE (n = 6) mice from day 
10 to day 24. (h) Mean fold gene expression change of Pgc1α in spinal cord of female WT- (n = 3) and Cpt1a-
mutated mice (n = 3). (i) Mean fold gene expression change of Nrf2 in spinal cord of female WT-ND (n = 4) and 
WT-HFD mice (n = 4). Asterisks indicate the level of statistical significance (*p < 0.05). Abbreviations: Cpt1a, 
carnitine palmitoyl transferase 1a with a p479l mutation; ND, normal diet, HFD, high fat diet. E, etomoxir; P, 
placebo; EAE, experimental autoimmune encephalomyelitis; MOG, Myelin-oligodendrocyte  glycoprotein35–55 
 (MOG35–55), CFA, Complete Freund’s Adjuvant; S.c., Subcutaneous; I.p., Intraperitoneal; Inj., Injection; WT, wild 
type. SEM: standard error of the mean. We acknowledge Servier Medical Art for the mouse illustration, which 
can be found at: https ://smart .servi er.com/. License; https ://creat iveco mmons .org/licen ses/by/3.0/. No changes 
were made to the drawing.
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Cpt1a-EAE mice found in this study (Fig. 2c–e) support the findings of low prevalence of MS in this northern 
indigenous population compared to the non-indigenous population in  Canada30,31.
Cpt1a is epigenetically regulated in the rat blood brain barrier. Cpt1a gene is a key regulator of 
long chain fatty acids metabolism. The transcriptional and post-transcriptional regulation of the Cpt1a in every 
living organism facilitate adaptation to the changing environment, especially to diet. Recently, Moody et  al. 
provided evidence for epigenetic regulation of Cpt1a by DNA methylation and histone modifications in liver of 
rats fed  HFD32. The human study of blood samples from the great Dutch famine also showed regulation of Cpt1a 
by DNA  methylation33. The Blood Brain Barrier (BBB) is the tight epithelium regulating the influx of, among 
others, metabolites into the brain. Therefore, we used primary BBB-associated cells (endothelium, astrocytes, 
pericytes) obtained from rats to investigate the effect of two histone deacetylase inhibitors (HDACi), valproic 
acid (VPA) and sodium butyrate (SB), on the expression of Cpt1a gene. Cpt1a exhibited significant expression 
changes in response to both HDACi in the pericytes (Fig. 3a), endothelium (Fig. 3b), and astrocytes (Fig. 3c). As 
expected, both HDACi led to the increased expression of the Cpt1a in pericytes and endothelial cells through 
augmented histone acetylation. Unexpectedly, expression of Cpt1a almost disappeared in the astrocytes. More 
investigation of the role of histone acetylation levels must be done to understand the precise mechanism of 
HDACi effect on the Cpt1a promoter.
Pharmacological and genetic inhibition of CPT1 downregulates disease progression in 
 SOD1G93A mice reflected on neurological scores and gene expression. Several studies have shown 
that both ALS patients and animal models mimicking ALS have a dysregulated metabolism of  lipids19,34. CPT1A 
and CPT1B are upregulated in the SOD1 mouse model mimicking familial  ALS20,35. Therefore, we tested the 
Figure 3.  Expression of Cpt1a and Cpt1c in primary rat BBB-associated cells following treatment with VPA 
and SB. (a) Relative gene expression of Cpt1a and Cpt1c in pericytes following treatment with VPA and SB. 
(b) Relative gene expression of Cpt1a and Cpt1c in endothelial cells following treatment with VPA and SB. (c) 
Relative gene expression of Cpt1a and Cpt1c in astrocytes following treatment with VPA and SB. Data expressed 
as relative expression to reference genes β-actin and Hprt1 ± SEM. Asterisks indicate the level of statistical 
significance (**p < 0.01, ***p < 0.001, ****p < 0.0001). Abbreviations: SB, sodium butyrate; VPA, valproic acid. 
SEM: standard error of the mean.
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effect of pharmacological inhibition of CPT1 by etomoxir in the  SOD1G93A model. The  SOD1G93A female mice 
(n = 9) were randomized into treatment with either etomoxir (5 mg/kg) (n = 4) or placebo (olive oil) (n = 5) from 
day 70 (baseline) (Fig. 4a). The  SOD1G93A mice receiving etomoxir  (SOD1G93A-E) showed significantly lower 
mean neurological score, increased grip strength, and higher latency to fall on the hangwire test compared to 
mice treated with placebo  (SOD1G93A-P) (Fig. 4b–d). Following the  SOD1G93A etomoxir experiment, we assessed 
gene expression in the lumbar spinal cord of the animals to evaluate whether the downregulation of CPT1 
affected inflammatory markers. We found that etomoxir-treated  SOD1G93A mice had a tendency towards lower 
expression of Ifn-ϒ, Casp1, and significant lower expression of IL-17α (Fig. 4e). This indicated that downregula-
tion of CPT1 reduces inflammation. These findings support previously presented data that dysregulated metabo-
lism is most likely associated with  ALS36.
To assess the role of CPT1A in the development and progression of ALS, we generated a  SOD1G93A mouse 
model with a heterozygote Cpt1a P479L mutation  (SOD1G93A/Cpt1a) with 66% CPT1A activity compared to the 
wildtype CPT1A (Fig. 4f). The development and progression of disease in the female  SOD1G93A/Cpt1a mice (n = 6) 
were compared to  SOD1G93A mice (n = 5) from day 70. The  SOD1G93A/Cpt1a mice had a significantly lower disease 
score, higher normalized grip strength and a higher latency to fall on the hang-wire test compared to  SOD1G93A 
mice in the early symptomatic stage of the disease but not later (Fig. 4g–i). Following termination of the animal 
experiments, we assessed changes in gene expression in the lumbar spinal cord to evaluate inflammation, oxi-
dative stress and mitochondrial functioning. We found that  SOD1G93A/Cpt1a mice had significantly lower Casp1 
expression, higher Nrf2 and significantly higher Pgc1α expression (Fig. 4j). This indicates that  SOD1G93A/Cpt1a had 
lower inflammation, better oxidative stress defense and mitochondrial biogenesis. Further, we assessed the levels 
of glucose and LDL in the serum of  SOD1G93A/Cpt1a mice and compared these to  SOD1G93A mice to assess whether 
the Cpt1a mutation affected the metabolism. Interestingly, we found that  SOD1G93A/Cpt1a had significantly lower 
levels of glucose and LDL (Fig. 4k). This indicates that CPT1A lipid metabolism plays a role in the development 
and progression of the disease.
Inhibition of CPT1 and CPT1A reverses disease progression in a chronic rotenone animal 
model mimicking Parkinson’s disease. Metabolic dysregulation was shown in several studies in both 
PD patients and animal models of PD (toxic and genetic)6,37. Furthermore, studies have found that β-oxidation 
is upregulated in PD  patients38,39. Rotenone is a pesticide which blocks the mitochondrial complex 1 and has 
been shown to upregulate CPT1. Therefore, the effect of pharmacological inhibition of CPT1 by etomoxir was 
evaluated in a chronic rotenone mouse model using C57Bl/6J male mice (Fig. 5a). Mice were randomized into 
a rotenone regimen (30 mg/kg daily, n = 20) or vehicle (0.5% Carboxymethylcellulose sodium salt; CMC, n = 5) 
for 32 days. The vehicle group served as healthy controls. At day 32, the mice were evaluated for symptoms. Two 
mice did not develop symptoms of PD, and was removed before initiation of treatment. The rotenone-induced 
mice were randomized into treatment with etomoxir (5 mg/kg, WT-R + E, n = 9) or placebo (olive oil, WT-R + P, 
n = 9) (Fig.  5a). The mice receiving CMC were treated with placebo (WT-V). The mice received 18  days of 
treatment over a period of 30 days (Fig. 5a). The WT-R + E mice had a significantly higher latency to fall on 
the rotarod compared to WT-R-P mice at day 60 (Fig. 5b). Moreover, etomoxir-treated mice had a significant 
increase in normalized grip strength compared to day 32 (Fig. 5c) and sensorimotor function in the cylinder test 
(Fig. 5d). These findings indicate that inhibition of CPT1 could restore motor- and sensorimotor function in the 
rotenone-induced PD-like C57Bl/6J mouse model.
To investigate whether CPT1A activity contributed to development of PD, we compared the Cpt1a-mutated 
male mice with WT male mice for sensitivity to chronic rotenone induced disease (Fig. 5e). Cpt1a-mutated mice 
(Cpt1a-R, n = 7) and wildtype C57Bl/6J mice (WT-R, n = 10) received rotenone for 32 days (Fig. 5e). Further, 
wildtype C57Bl/6J mice received treatment with vehicle (WT-v, n = 5) for 32 days. The vehicle group served as 
healthy controls. At day 32, Cpt1a-R mice had a significantly higher latency to fall on the rotarod (Fig. 5f), a 
significantly higher normalized grip strength (Fig. 5g), and a significantly higher sensorimotor function in the 
cylinder test (Fig. 5h) compared to WT-R mice. This finding highlights that Cpt1a-mutated mice, which have a 
down-regulated lipid metabolism, were resistant to rotenone-induced PD. However, more mechanistic studies 
are warranted.
Cpt1a‑mutated mice have alternations in the gut microbiome. The role of gut microbiota in the 
development and progression of CNS diseases has been intensively studied in the last  decade40. Based on our 
findings in the EAE (Fig. 1),  SOD1G93A (Fig. 4) and chronic rotenone mouse models (Fig. 5), were Cpt1a-mutated 
mice showed resistance towards disease induction- and progression. We hypothesized that the Cpt1a p479l 
mutation might have affected the gut microbiota composition. To test this hypothesis, 16S rRNA sequencing 
were performed on fecal samples from male Cpt1a p479l mutated mice (n = 6) and male C57Bl/6J mice (n = 6). 
First, we assessed α-diversity using Shannon and Simpson index and found no differences between the groups 
(Fig. 6a). Next, we constructed heat maps at the phylum-, family- and genus level (Fig. 6b–d). At the phylum 
level, the 5 most abundant bacterial communities were firmicutes, bacteroidetes, verrucomicrobia, proteobacteria 
and actinobacteria (Fig. 6b). Interestingly, the abundance of verrucomicrobia and proteobacteria were remark-
ably low in the Cpt1a-mutated- compared to the WT mice, where actinobacteria were more prevalent. Follow-
ing this, we constructed a heat map at the family level illustrating the 10 most abundant communities (Fig. 6c). 
Lachnospiraceae was remarkably more abundant in the Cpt1a-mutated mice, whereas akkermansiaceae- and 
rikenellaceae were less abundant. Subsequently, we assessed the 20 most prevalent bacterial communities at the 
genus level (Fig. 6d). Interestingly, the Cpt1a-mutated mice had higher abundance of faecalibaculum- and lower 
abundance of akkermansia-, alistepes communities compared to WT mice (Fig. 6d). Following the heap map 
analyses, we assessed significant differences at the genus level between Cpt1a-mutated- and WT mice and found 
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132 communities with significant differences between the two groups (Supplementary Table 1). This is the first 
time that CPT1A activity has been shown to affect the gut microbiota composition.
Discussion
Neurodegenerative diseases such as MS, ALS, and PD, have a complex, and as of yet, unresolved origin and 
pathogenesis. As a result, only treatments that address specific symptoms exists at the moment. Here, we have 
presented that MS, ALS, and PD are characterized by local, and systemic changes in metabolism. Based on a 
CPT1A mutation found in the Inuit population, which seems to confer resistance to neurodegeneration by 
reducing CPT1A activity by 78%, we decided to test the effect of CPT1A de-activation in neurodegeneration in 
two ways: by pharmacologically blocking CPT1, and by creating a new Cpt1a p479l  mice26. The findings from 
this study revealed that the Cpt1a-mutated mice are resistant to the development of not only EAE, but also PD 
and to some extent ALS. In addition, we tested the efficacy of a CPT1-antagonist, etomoxir, on the same animal 
models mimicking MS, ALS, and PD and revealed that it could reverse disease progression (Figs. 1, 4, 5).
CPT1, in its three isoforms, is regulated by the Peroxisome Proliferator Activated-Receptors (PPARs) in a 
tissue-dependent  manner41–43. PPARs are regulators of multiple pathways including glucose- and lipid metabo-
lism and the immune  system44–46. As heterodimers with retinoid X receptor, they target genes that are involved in 
the regulation of mitochondrial- and peroxisomal fatty acid oxidation, fatty acid transport, glucose transport and 
apolipoprotein synthesis and inflammatory enzymes. Furthermore, they regulate oxidants and chemoattractant 
ligands, differentiation and recruitment of T cells and cell apoptosis among  others47,48. PPARs have been associ-
ated with CNS diseases in humans and in vivo models including MS, EAE, ALS,  SOD1G93A, PD, and rotenone 
 models49–53. Interestingly, several studies have shown that PPAR-α and PPAR-ϒ agonists ameliorate disease or 
disease progression in EAE-, rotenone-, and the  SOD1G93A mouse models through mechanisms such as decreased 
demyelination, inhibition of Th1 differentiation and IFN-ϒ  production54–56. Moreover, PPAR-α- and ϒ agonists 
decrease oxidative stress and increase mitochondrial biogenesis through Pgc1α in these  models52,57. Etomoxir, 
our CPT1-antagonist, has been shown to upregulate PPAR-α58 and PPAR-ϒ59, which could explain the positive 
clinical effects seen in the EAE- (Fig. 1),  SOD1G93A (Fig. 4) and rotenone (Fig. 5) models following treatment. 
Furthermore, Pgc1α was upregulated following etomoxir treatment (Fig. 1e) and Cpt1a mutation (Fig. 1k, 4j) 
indicating that downregulation of the metabolism of lipids by CPT1 has a positive effect through PGC1α.
Inhibition of CPT1 by etomoxir has been shown to downregulate the production of reactive oxygen  species60. 
We found a tendency towards a decreased gene expression of Nox-2 and Ho-1 in the hindbrain in the EAE mod-
els following downregulation of CPT1, and CPT1A (Fig. 1d–e,k). Nox-2 and Ho-1 have previously been found 
upregulated in MS, and  EAE61,62. We also found, a tendency towards, upregulation of Nrf2, previously shown 
to protect against oxidative stress and correlated with disease activity in  SOD1G93A model, in the  SOD1G93A/Cpt1a 
mice (Fig. 4j)63.
We have also previously shown that blocking CPT1 using etomoxir reduces demyelination, and increase 
apoptosis of MOG specific T-cells, decreases production of the inflammatory cytokine IL-17, and decrease 
production of IL-664,65. We found that Il-17α expression was significantly downregulated in the mid-, and hind-
brain of EAE-Cpt1a mice (Fig. 1i) and  SOD1G93A mice following etomoxir treatment (Fig. 4e). This indicates 
that downregulation of the metabolism of lipids through CPT1 results in a dampening of inflammation, which 
is supported by lower IL-6 and TNF-α levels in serum from the EAE experiments (Fig. 1f,m) and lower inflam-
matory gene expression in the spinal cord from the  SOD1G93A experiments (Fig. 4e,j). Several studies have shown 
that metabolism plays a central role in the regulation of immune  cells14,64,66. Some studies involved the use of 
etomoxir which was shown to downregulate the inflammatory properties of classical dendritic cells (DC) and 
increase insulin sensitivity by upregulating the metabolism of glucose through  GLUT415,67,68. Correspondingly, 
we found that Cpt1a-mutated mice presented with changes in serum glucose, and lipoproteins in serum indi-
cating changes in metabolism (Fig. 2a–d). These changes were most profound in the disease progression in the 
 SOD1G93A/Cpt1a study (Fig. 4k).
Multiple factors can upregulate the metabolism of lipids through CPT1, such as a diet rich in high saturated 
fat and refined sugars. Multiple studies have found that HFD increases disease activity in EAE, ALS, and PD 
in vivo  models69,70. Remarkably, here we found that Cpt1a-EAE mice receiving HFD had significantly lower 
disease activity compared to WT-EAE mice receiving HFD (Fig. 2g). We hypothesized that this severe disease 
Figure 4.  The efficacy of pharmacological and genetic inhibition of CPT1 in  SOD1G93A model of ALS. (a) 
Experimental setup for the  SOD1G93A-etomoxir study using female mice. (b) Neuroscore of female  SOD1G93A-E 
(n = 4) and  SOD1G93A-P (n = 5) mice. (c) Latency to fall on the hang-wire test of female  SOD1G93A-E (n = 4) 
and  SOD1G93A-P (n = 5) mice. (d) Normalized grip strength of female  SOD1G93A-E (n = 4) and  SOD1G93A-P 
(n = 5) mice. (e) Mean fold expression change of Ifn-ϒ, Il-17α and Casp1 in spinal cord of  SOD1G93A-E and 
 SOD1G93A-P mice (n = 3–4). (f) Experimental setup for the  SOD1G93A/Cpt1a study comparing heterozygote Cpt1a 
mutation with  SOD1G93A female mice without mutation. (g) Neuroscore of  SOD1G93A (n = 5) and  SOD1G93A/Cpt1a 
(n = 6) mice. (h) Latency to fall on the hangwire test of  SOD1G93A (n = 5) and  SOD1G93A/Cpt1a (n = 6) mice. (i) 
Normalized grip strength of  SOD1G93A (n = 5) and  SOD1G93A/Cpt1a (n = 6) mice. (j) Mean fold expression change 
of Casp1, Nrf2 and Pgc1α in spinal cord of  SOD1G93A and  SOD1G93A/Cpt1a (n = 3–4). (k) Level of glucose and 
LDL in serum  SOD1G93A and  SOD1G93A/Cpt1a (n = 4) mice. Asterisks indicate the level of statistical significance 
(*p < 0.05, **p < 0.01). Abbreviations:  SOD1G93A, superoxide dismutase 1 glycine 93 changed to alanine; 
Cpt1a, heterozygote carnitine palmitoyl transferase 1a with a p479l mutation; E, etomoxir; P, placebo. ALS: 
amyotrophic lateral sclerosis. SEM: standard error of the mean. We acknowledge Servier Medical Art for the 
mouse illustration, which can be found at: https ://smart .servi er.com/ with the following license; https ://creat 
iveco mmons .org/licen ses/by/3.0/. No changes were made to the drawing.
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Figure 5.  The efficacy of pharmacological and genetic inhibition of CPT1 in rotenone models of PD. (a) Experimental 
setup for the chronic rotenone mouse model treated with etomoxir using male C57Bl/6J mice. (b) Latency to fall of 
the rotarod at day 60 for WT-R-E (n = 9), WT-R-P (n = 9) and WT-V (n = 5). (c) Normalized grip strength for WT-R-E 
(n = 9), WT-R-P (n = 9) and WT-V (n = 5) at day 32 before treatment and at day 60. (d) Number of rears in the cylinder 
test for WT-R-E (n = 9), WT-R-P (n = 6) and WT-V (n = 5) at day 32 before treatment and at day 56. (e) Experimental 
setup for the chronic rotenone mouse model using Cpt1a-mutated mice and male C57Bl/6J mice. (f) Latency to fall of 
the rotarod at day 32 for Cpt1a-R (n = 7), WT-R-P (n = 10) and WT-V (n = 5). (g) Normalized grip strength at day 32 
for Cpt1a-R (n = 7), WT-R-P (n = 10) and WT-V (n = 5). (h) Number of rears in the cylinder test at day 32 for Cpt1a-R 
(n = 5), WT-R-P (n = 10) and WT-V (n = 5). Asterisks indicate the level of statistical significance (*p < 0.05, **p < 0.01). 
Abbreviations: Cpt1a, carnitine palmitoyl transferase 1a with a p479l mutation; R, rotenone; E, etomoxir; P, placebo; V, 
vehicle; WT, wild type. PD: Parkinson’s’ Disease. SEM: standard error of the mean. We acknowledge Servier Medical 
Art for the mouse illustration, which can be found at: https ://smart .servi er.com/ with the following license https ://creat 
iveco mmons .org/licen ses/by/3.0/. No changes were made to the drawing.
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progression could be due to several factors such as dysregulated mitochondrial function (Figs. 1k, 2h), decreased 
oxidative defense mechanisms (Figs. 1k, 2i), and inflammation (Fig. 2i) in WT-EAE mice receiving HFD. Another 
factor that could upregulate CPT1 lipid metabolism might be chronic hyperactivation of the HPA-axis leading 
to high levels of circulating corticosteroids, which has been reported for MS, ALS and  PD71–73. The chronic 
hyperactivation of the HPA-axis results in glucocorticoid receptor resistance and runaway inflammation due to 
the failure of the negative glucocorticoid feedback  mechanism74. Furthermore, dysregulation of the HPA-axis 
results in diminished secretion of insulin, and insulin resistance, resulting in a shift from glucose metabolism 
to lipid metabolism. In turns, this leads to more inflammation and catabolism of nearby lipids for energy  gain75.
Our data also indicates that Cpt1a expression also regulates the function of the endothelial cells of the blood 
brain barrier (BBB). The BBB is crucial for healthy brain function, but remains a big challenge in drug  delivery76. 
Many neurodegenerative diseases such as MS, ALS, and PD exhibit compromised BBB. The etiology of the leaky 
BBB is multifactorial and remains very partially understood. Here, we showed that the expression of Cpt1a in 
response to commonly prescribed drugs, VPA, and another HDACi inhibitor SB, affects BBB-associated cells 
(Fig. 3). Cpt1a expression increases significantly in pericytes and endothelial cells in response to treatment 
with VPA and SB, which is likely to lead to an increase in lipid metabolism at the blood–brain transition zone 
(Fig. 3a,b). Astrocytes, however, show different Cpt1a expression profiles depending on environmental and treat-
ment cues, which might indicate that epigenetic mechanisms could be cell-specific (Fig. 3c). Recently, changes 
in the Cpt1a promoter epigenetic profile were reported in the livers of rats exposed to HFD, which supports 
the possibility that lipid metabolism can also have influence on the function and integrity of  BBB32. Changes in 
Figure 6.  Cpt1a-mutated mice have changes in their gut microbiota compared to WT mice. (a) Shannon and 
Simpson α-diversity measures in male Cpt1a-mutated (n = 6) and WT mice (n = 6). (b) The five most abundant 
bacterial communities at phyla level in male Cpt1a-mutated (n = 6) and WT mice (n = 6). (c) The ten most 
abundant bacterial communities at family level in male Cpt1a-mutated (n = 6) and WT mice (n = 6). (d) The 20 
most abundant bacterial communities at genus level in male Cpt1a-mutated (n = 6) and WT mice (n = 6). Heat 
maps illustrate the relative abundance of the bacterial communities. Abbreviations: Cpt1a, carnitine palmitoyl 
transferase 1a with a p479l mutation; WT, wild type.
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histone H3 methylation significantly affected binding of the transcription factor PPARα to the Cpt1a  promoter32. 
Moreover, acute hyperglycemia—due to an imbalanced glucose/lipid metabolism—has been shown to cause 
persistent epigenetic changes, including changes to Cpt1a77. These data, together with the data presented here, 
indicate that Cpt1a does respond to metabolic state through epigenetic  processes32.
Our study has also shown that mice with a Cpt1a mutation exhibited a shift in their microbiota. The gut 
microbiota has been correlated with the development or protection from CNS diseases and with the modulation 
of the HPA-axis response from early  life78,79. Furthermore, stimulates the intestinal gluconeogenesis, modulates 
glucose- and lipid metabolism, and plays a role in insulin resistance and  inflammation80. Transplantation of feces 
from patients with neurodegenerative diseases exacerbates disease severity in animal models mimicking these 
 diseases81,82. This indicates that the gut microbiome affects the CNS through involvement of systemic mecha-
nisms. Our data confirms this link between the microbiota and the metabolism by showing that the de-activation 
of CPT1A modulates the gut microbiota (Fig. 6b–d). Interestingly, we found that several of the significantly 
changed bacterial communities between Cpt1a-mutated mice and WT mice have been reported to play a role in 
CNS diseases (Supplementary Table 1). Alistipes communities have been found significantly increased in humans 
with mood  disorders83 and were correlated with the volatile fatty acids and cortisol  levels84. Further, a higher 
abundance of Alistipes has been associated with type 2  diabetes85. Lachnospiraceae communities have been found 
decreased in CNS diseases and were generally more abundant in the Cpt1a mutant mice (Fig. 6c)86. Interestingly, 
Akkermansia communities have been found to increase the gut permeability and are correlated with PD disease 
severity and was less abundant in the Cpt1a-mutant mice (Fig. 6c–d)87. Faecalibaculum communities were sig-
nificantly more abundant in the Cpt1a-mutant mice (Supplementary Table 1) and have been found decreased 
in multiple CNS  diseases86. The bacterial genus Blautia has been found with anti-inflammatory properties and 
Figure 7.  Novel proposed framework of CNS-related disease pathogeneses. We acknowledge Maria Rasmussen 
for drawing the figure.
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those were significantly higher in the Cpt1a-mutant mice (Supplementary Table 1). Interestingly, Blautia has 
been found to be decreased in PD  patients5. Moreover, Rikenellaceae communities were significantly decreased 
in the Cpt1a-mutant mice (Fig. 6c). Interestingly, Rikenellaceae has been found elevated following  HFD88. In 
addition, the gut microbiota is directly coupled with the diet of the animal or patient. A shift in microbiota has 
been seen in people under a western diet with high levels of fats and refined  carbohydrates89. Through our study, 
we have confirmed that a high fat diet worsens disease severity and progression. The important question remains 
unanswered on whether the microbiota is changed due to the diet or due to the disease, and whether the disease 
is induced due to the change in microbiota or due to the diet itself. Our study indicates that it is the former: 
the CPT1A-mediated lipid metabolism modifies and possibly regulates the microbiota in the gut. Our data also 
confirms that there is a strong association between microbiota, diet, and disease development or progression. 
This suggests an important link between these environmental cues and the regulation of gut microbiota.
Based on the data presented here, we therefore suggest a new model to explain the development and pro-
gression of CNS diseases in which an imbalance between the metabolism of lipids and glucose is at the root of 
neurodegeneration (Fig. 7). A healthy state requires a homeostatic equilibrium between the HPA axis, immune 
system, microbiota, mitochondrial functioning, metal metabolism, redox state, and glucose-lipid metabolism. 
Our new model visualizes the possible interplay between these complex processes, and shows that, when imbal-
anced, they raise the likelihood of CNS disease development. Our study confirms that neurodegeneration is a 
multifactorial process: no single mechanism seems capable of explaining the complex nature of neurodegenera-
tion in diseases such as MS, ALS, and PD. However, our experiments highlighted a key node in maintaining 
homeostasis: the activity of CPT1. This is the first time that a common, critical, and underlying pathological 
mechanism has been established for several neurodegenerative diseases based on experimental data. This model 
provides an open platform for future experiments and therapeutic targets.
In conclusion, we have provided evidence that CPT1 is a potential key candidate for the regulation of neuro-
degeneration, acting as the gate-keeper molecule in the homeostasis of lipid and glucose metabolism. Through 
pharmacological and animal model-based inhibition of CPT1, we have clearly shown that blocking the dys-
regulated metabolism of lipids offer profound beneficial effects in EAE,  SOD1G93A/Cpt1a and rotenone diseases 
models through decreased inflammation, oxidative stress and increased mitochondrial biogenesis. Importantly, 
have demonstrated that MS, ALS, and PD, seems to share a common dysregulated metabolism of lipids. We have 
provided evidence that Cpt1a is epigenetically regulated, and that CPT1A lipid metabolism modulates the gut 
microbiome. Furthermore, we have proposed a new model to understand and target neurodegenerative diseases 
in future experiments.
Methods
Animals. The animal experiments were conducted according to NIH guidelines and were approved by the 
Danish National Committee for Ethics in Animal Experimentation (Mouse EAE: 2017-15-0201-01240, mouse 
ALS: 2017-15-0202-00088, mouse PD: 2017-15-0201-01328). All animals were housed in IVC cages and main-
tained under standardized conditions with a 12 h light–dark cycle and ad libitum access to food and water.
Generation of Cpt1a P479L mice. To examine the role of CPT1A activity, a mouse line (B6J-
Cpt1a < em1Nki >) expressing the Inuit mutant allele Cpt1a P479L (Cpt1a < em1Nki > , MGI number: 5810634) 
was generated and genotyped as previously  described26.
Generation of  SOD1G93A/Cpt1a mice. To test the role of Cpt1a activity in the Sod1 g93a mouse model, mim-
icking ALS, we generated  SOD1G93A mice with a Cpt1a point mutation. Briefly, B6.Cg-Tg(SOD1*G93A)1Gur/
J90 mice were purchased from Jackson Laboratory (Bar Harbor, Main, USA). Mice were acclimated for 
3 weeks at 21 °C and kept in a high barrier facility (The Rodent Facility, Aalborg University Hospital). B6.Cg-
Tg(SOD1*G93A)1Gur/J males were crossed with homozygote B6J-Cpt1a < em1Nki > female mice. Litters were 
genotyped using DNA extracted from ear punch tissue using DNA kit (Zymo Research). Mice were genotyped 
by RT-qPCR using for the expression of the Sod1 g93a mutation using primer sequences:  (SOD1G93A forward: 
GGG AAG CTG TTG TCC CAA G,  SOD1G93A reverse: CAA GGG GAG GTA AAA GAG AGC, Internal posi-
tive control forward: CAC GTG GGC TCC AGC ATT, Internal positive control reverse: TCA CCA GTC ATT 
TCT GCC TTT G) (TAG Copenhagen) and the previously mentioned primer sequences for Cpt1a p479l26. 
RT-qPCR was performed as described below.  SOD1G93A female mice with a heterozygote Cpt1a p479l mutation 
 (SOD1G93A/Cpt1a) (n = 6) was used in subsequent experiment.
EAE experiments. Sex is known to affect susceptibility to specific diseases and because women are more 
susceptible to the development of MS, female mice were used in the EAE  models1.To test the effect of blocking 
CPT1 by a CPT1-blocker, an EAE model was  used26. C57BL/6J mice were purchased from Janvier Laboratory 
(Le Genest-Saint-Isle, France) and were acclimated for 3 weeks at 21 °C in a high barrier before initiating experi-
ment and kept in the Animal Facility at Aalborg University. The 8-week-old C57BL76J female mice (n = 12) were 
anesthetized with isoflurane and immunized subcutaneously in the base of the tail with 200 μg  MOG35–55 (Pep-
mic) emulsified in complete Freund´s adjuvant (CFA) (Becton Dickinson) containing Mycobacterium tuberculo-
sis (Becton Dickinson). All mice received an intraperitoneal injection of 500 ng pertussis toxin (Sigma-Aldrich) 
on the day of immunization and 2 days later. The mice were monitored daily and weighed and scored clinically 
according to a scale from 0 to  526. The mice were not permitted to lose more than 20% body weight and to go 
beyond score 4. Mice (n = 7) were treated with  etomoxir25 (5 mg/kg) (Meta-IQ ApS) or placebo (olive oil) treat-
ment (n = 5) from day 10. To test whether CPT1a activity modulated EAE disease severity, we conduct an animal 
experiments using female Cpt1a-mutated mice. Eight-week-old C57BL76J female mice (n = 5) and Cpt1a p479l 
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female mice (n = 6) were induced with EAE as described above. The mice were assessed daily for animal welfare, 
weighed and scored clinically according to a scale from 0 to  526. The mice were not permitted to lose more than 
20% body weight and to go above a clinical score of 4. Further, to test the effect of high fat diet, 8-week-old 
C57BL76J female mice (n = 5) and Cpt1a p479l female mice (n = 6) were induced with EAE as described above 
and from day 10, the mice received high-fat diet (HFD) (kcal% respectively: protein 20, carbohydrate 20, fat 60, 
Brogaarden, Denmark; based on D12492 research diets, New Brunswick, USA) throughout the experiments.
SOD1 G93A experiments. Humans with SOD1 mutations have an approximately female/male ratio of 1 
and because of this females were chosen for the  SOD1G93A  model17.To test whether blocking CPT1 could modu-
late disease progression in ALS, we used the SOD1 G93A mouse model. B6.Cg-Tg(SOD1*G93A)1Gur/J mice 
were purchased from Jackson Laboratory (Bar Harbor, Main, USA)90. Mice were kept in a high barrier facility 
(The Animal Facility, Aalborg University). B6.Cg-Tg(SOD1*G93A)1Gur/J male mice were breed with C57Bl/6J 
female mice. Genotypes were evaluated using DNA extracted from ear tissue punches. RT-qPCR was performed 
using previously described primer sequences according to  protocol91. Transgenic  SOD1G93A female mice were 
used for experiments (n = 14).  SOD1G93A mice were randomized into treatment with either etomoxir (5 mg/kg 
dissolved in olive oil) or placebo (olive oil) daily by oral gavage from day 70 (baseline) (Fig. 4a).  SOD1G93A mice 
were evaluated with a neurological score system weekly as previously  described92 and weighted two times a week. 
 SOD1G93A mice and ALS patients’ losses muscle strength as the disease progresses and therefore muscle strength 
were assessed weekly using a grip strength meter (Bioseb, France). Grip strength were measured in grams and 
normalized to weight according to  protocol93. Furthermore, neurological function and muscle strength were 
assessed using the hang-wire test as previously  described92,93. Briefly, mice were put on a wire lid and gently turn 
upside down. The time until the mice fell down was measured (latency to fall), cutoff time was set to 180 s. Each 
mice performed three trails and the highest value was used for statistics as previously  described92,94. Mice were 
euthanized when they reached a neurological score of 4 or above or if they had a weight loss of 20% or more 
according to ethical guidelines. The  SOD1G93A/Cpt1a mice (n = 6) were evaluated with the same procedures from 
day 70 until day 127 (Fig. 4f).
Rotenone experiments. Men have a higher incidence of PD compared to women and, accordingly, we 
conducted our chronic rotenone model using male  mice3. To assess whether blockage of CPT1 or CPT1A activ-
ity had a role in PD, we used a chronic rotenone mouse model as previously  described95. Rotenone has been 
shown to upregulate lipid metabolism through  CPT196. Briefly, C57BL/6J male mice were obtained from Janvier 
Labs (Le Genest-Saint-Isle, France). Mice were acclimated for 3 weeks at 21 °C in a high barrier animal facility. 
Cpt1a p479l mice were generated and breed as previously  described26. Mice were 9 weeks old when the experi-
ment initiated. Mice were weighted once a week throughout the experiments.
Rotenone is a pesticide and has been used in several animal models of  PD53,95,97,98. We used a chronic oral 
gavage, dosing regimen similar to the process reported by  others95,97. Mice were randomized into a group receiv-
ing 30 mg/kg rotenone (Sigma-Aldrich, Cat. 83-79-4) suspended in 0.5% Carboxymethylcellulose sodium salt 
(CMC) (Sigma-Aldrich, Cat. 9004-32-4) or a group receiving CMC as vehicle daily.. Animals were evaluated by 
grip strength test as previously  described93. Rotarod test (Rotamex-5 RotaRod, Columbus Instruments, Colum-
bus, Ohio, USA) with an acceleration from 4 to 40 RPM over 180 s. Mice were acclimatized to the rotarod over 
three consecutive days. Each mouse was tested 3 times to obtain a mean latency to fall (s). Mice were evaluated 
for sensorimotor symptoms by the cylinder test as previously  described99.
For the etomoxir treatment experiment the following groups were used: wildtype mice receiving rotenone 
(n = 20), and wildtype mice receiving vehicle (n = 5) for 32 days. Animals, which did not show sign of disease 
defined by the presence of minimum two of the following factors: lower grip strength, lower latency to fall on the 
rotarod and/or lower number of rears in the cylinder test compared to the healthy control group, was excluded 
from treatment groups (n = 2) at day 32. At day 33 12 weeks old C57BL/6J mice receiving rotenone were rand-
omized into two groups (Fig. 4a). One receiving etomoxir at 5 mg/kg dissolved in olive oil (n = 9) and another 
receiving only olive oil as placebo (n = 9). At this point, the daily administration of rotenone was changed to every 
second day. This intervention was given every second day in between the rotenone and CMC administration, 
day 33, 35 etc. At day 62, the experiment ended. Thus, making it a total of 43 rotenone administrations span-
ning along 61 days. The etomoxir intervention group had 18 administrations of etomoxir over a span of 28 days, 
receiving etomoxir without rotenone intervention from day 50 until 56 and again form day 58 to 60. Animals 
were evaluated for rotenone induced behavioral deficits at day 32 and day 60, except for the cylinder test which 
was conducted at day 32 and day 56.
The following groups were used in the Cpt1a-mutant experiment; Cpt1a-mutant mice receiving rotenone 
(n = 7), wildtype mice receiving rotenone (n = 10), and wildtype mice receiving vehicle (n = 5) for 32 days (Fig. 4e). 
Animals were evaluated for rotenone induced behavioral deficits using rotarod, grip strength, and cylinder test 
at day 32.
chronic high fat diet model and Cpt1a mutant versus wildtype experiment. 10 week old female 
C57BL/6J mice (n = 8) from our animal facility were randomized into receiving either normal diet (kcal% 
respectively: protein 29, carbohydrate 65.5, fat 5.5, Brogaarden, Denmark) or HFD (kcal% respectively: protein 
20, carbohydrate 20, fat 60, Brogaarden, Denmark; based on D12492 research diets, New Brunswick, USA) for 
10 weeks as previously  described100. After 10 weeks the mice were terminated and spinal cord tissue were quickly 
harvested and stored at − 80 °C until further analyses. For assessment for differences in serum glucose, LDL, 
and HDL we used 10 weeks old C57Bl/6J (n = 15), and Cpt1a mutant male mice (n = 12). Blood was sampled by 
retroorbital puncture, and serum was obtained as described below.
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Serum glucose, LDL and HDL analyses. Animals were placed in cages without access to food for 1 h 
before termination. Blood were obtained from animals and placed at room temperature for minimum 40 min. 
Afterwards samples were centrifuged at 3500  g for 15  min and the supernatant was transferred and stored 
at − 80 °C until further analyses. Serum analyses of glucose- (Crystal Chem, Cat. 81692), LDL- (Crystal Chem, 
Cat. 79980) and HDL- (Crystal Chem, Cat. 79990) levels were performed using commercial mouse assay kits 
according to the manufactures protocol. Samples- and standards were run in duplicates and were analyzed using 
a multiplate reader (PerkinElmer). Concentrations were estimated according to standard curve methods as 
described in the manufacture’s protocols.
Gene expression analyses in EAE‑ and  SOD1G93A models. RNA was extracted from the hindbrain, 
midbrain and frontal lobe for the EAE studies and lumbar spinal cord for the  SOD1G93A experiments as previ-
ously  described26. cDNA was synthesized as previously described according to the manufactures  protocol26. 
Reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) was performed as previously described 
using β-actin as housekeeping  gene26. Samples were run in triplicates for the EAE studies and duplicates for the 
 SOD1G93A, Cpt1a versus WT and chronic high fat diet model. Following RT-qPCR fold gene expression was 
determined using  2−∆∆CT method as previously  described26. Nox-2, Ho-1, Nrf2- and Pgc1α primer sequences were 
as previously  described26. The following primers were purchased from QIAGEN; Casp1 (PPM02921E), Il-17α 
(PPM03023A-200), Ifn-ϒ (PPM03121A-200).
ELISA. ELISA was performed using commercial kits for IL-6 (Invitrogen, Cat. 88-7064) and TNF-α (Inv-
itrogen, Cat. 88-7324). Procedures were done according to manufactures protocols. Standards- and samples 
were run in duplicates. OD values were read at 450 nm using a multiplatereader (PerkinElmer). Calculation of 
concentrations were done according to manufactures protocol using standard curve methods.
Microbiota analyses. To assess whether CPT1a activity had any impact on gut microbiome community, 
we investigated changes in the gut microbiota using male Cpt1a-muated mice and male wildtype mice. Briefly, 
fecal samples were collected from 12 week old male Cpt1a mice and male wildtype C57Bl/6J mice from Aalborg 
University animal facility and quickly stored at − 80 °C until further processing. Animals were housed together 
under identical conditions (bedding, pellets, water and ventilation). 16S rRNA analyses were performed by 
DNASense APS (Aalborg, Denmark).
DNA extraction. DNA extraction was performed using the standard protocol for FastDNA Spin kit for 
Soil (MP Biomedicals) with the following exceptions. 500 L of sample, 480 L Sodium Phosphate Buffer and 120 
L MT Buffer were added to a Lysing Matrix E tube. Bead beating was performed at 6 m/s for 4 × 40 s. Gel elec-
trophoresis using Tapestation 2200 and Genomic DNA screentapes (Agilent) was used to validate product size 
and purity of a subset of DNA extracts. DNA concentration was measured using Qubit dsDNA HS/BR Assay kit 
(Thermo Scientific).
Bacterial and Archaeal community analysis targeting 16S V4 rRNA. Bacteria and Archaea, 16S 
rRNA region V4 sequencing libraries were adapted by a custom protocol established on an Illumina protocol 
(Illumina, 2015) . Extracted DNA (maximum 10 ng) was used as template for Polymerase Chain Reaction ampli-
fication of the Bacteria and Archaea, 16S rRNA gene region V4 amplicons. Each Polymerase Chain Reaction 
reaction (25µL) contained dNTPs (100 M of each), MgSO4 (1.5 mM), Platinum Taq DNA polymerase HF (0.5 
U/reaction), Platinum High Fidelity buffer (1X) (Thermo Scientific) and tailed primer mix (400 nM of each 
forward and reverse primer). Polymerase Chain Reaction was done with the following settings: denaturation 
at 95 C for 2 min, 30 cycles of amplification (95 °C for 15 s, 55 °C for 15 s, 72° C for 50 s) and a terminal elon-
gation at 72 °C for 5 min. Polymerase Chain Reaction reactions were performed in duplicate for each sample 
and the duplicates were pooled following Polymerase Chain Reaction. The forward and reverse tailed primers 
were designed according  to101 and contain primers targeting the Bacteria and Archaea, 16S rRNA gene region 
V4: [806RB] GGA CTA CNVGGG TWT CTAAT and [515FB GTG YCA GCMGCC GCG GTAA]102. The ampli-
con libraries were purified based to the manufactures protocol using Agencourt Ampure XP Beads (Beckman 
Coulter) with a sample bead to ratio of 5:4. DNA was eluted in 25 µL of nuclease free water (QIAGEN). DNA 
concentration was confirmed using Qubit dsDNA HS Assay kit (Thermo Scientific). Gel electrophoresis using 
Tapestation 2200 and D1000/High sensitivity D1000 screentapes (Agilent) was used to validate product size 
and purity of a subset of sequencing libraries. Sequencing libraries were established from the cleaned amplicon 
libraries using a second Polymerase Chain Reaction. Each reaction (25 µL) contained PCRBIO HiFi buffer (1x), 
PCRBIO HiFi Polymerase (1 U/reaction) (PCRBiosystems), adaptor mix (400 nM of each forward and reverse) 
and up to 10 ng of amplicon library template. Polymerase Chain Reaction was done as follows: denaturation at 95 
C for 2 min, 8 cycles of amplification (95 °C for 20 s, 55 °C for 30 s, 72 °C for 60 s) and a final elongation at 72 °C 
for 5 min. The final sequencing libraries were purified according to the manufactures protocol using Agencourt 
Ampure XP Beads (Beckman Coulter) with a sample to bead ratio of 5:4. DNA was eluted in 25 µL of nuclease 
free water (QIAGEN). DNA concentration was quantified using Qubit dsDNA HS Assay kit (Thermo Scientific). 
Gel electrophoresis using Tapestation 2200 and D1000/High sensitivity D1000 screentapes (Agilent,) was used 
to validate product size and purity of a subset of sequencing libraries.
The purified libraries were pooled in equiM concentrations and diluted to 2 nM. The samples were sequenced 
paired-end (2 × 300 bp) on a MiSeq (Illumina, USA). Sequencing was performed using Reagent kit version 3 
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(Illumina, USA) following the Illumina guidelines for preparing and loading samples on the MiSeq. > 10% PhiX 
control library was spiked in to overcome low complexity issues often observed with amplicon  samples103.
Bioinformatic processing. Forward and reverse reads were trimmed for quality using Trimmomatic v. 
0.32104 with the settings SLIDINGWINDOW:5:3 and MINLEN: 225 . The trimmed forward and reverse reads 
were merged using FLASH v. 1.2.7105 with the settings -m 10 -M 250. The trimmed reads were dereplicated 
and formatted for use in the UPARSE  workflow106. The dereplicated reads were clustered, using the usearch v. 
7.0.1090 -cluster_otus command with default settings. OUT abundances were estimated using the usearch v. 
7.0.1090 -usearch_global command with -id 0.97 -maxaccepts 0 -maxrejects 0. Taxonomy was assigned using 
the RDP  classifier107 as implemented in the parallel_assign_taxonomy_rdp.py script in  QIIME108, using—con-
fidence 0.8 and the SILVA database, release  132109. The results were analysed in R v. 3.5.1 (R Core Team, 2017) 
through the Rstudio IDE using the ampvis package v.2.4.2103.
Primary cell cultures and treatment. Brain capillary endothelial cells (BCEC) and pericytes were iso-
lated from 2 to 3 weeks old Sprague–Dawley rats. Primary BCECs were cultured in DMEM/Nutrient F-12 Ham 
(Invitrogen, Cat. 31331-028) with 10% plasma derived bovine serum (First Link, Wolverhampton, United King-
dom, UK), insulin-Transferrin-Selenium (1:100) (Sigma Aldrich I1884), gentamicin sulphate (10 μg/ml), and 
basic fibroblast growth factor (1 ng/ml) (Roche). To ensure a pure BCEC culture, puromycin (1 μl/ml) (Sigma-
Aldrich) was added to the medium.
Primary astrocytes were isolated from neonatal Sprague–Dawley rats and cultured in DMEM (Invitrogen, 
Cat. 10106-169), fetal calf serum (10%) (Gibco, Cat. 10106-169), and gentamicin sulphate (10 μg/ml) (Sigma-
Aldrich, Cat. 17-518Z).
After cell culturing the cells were either used as control cells (n = 3) and/or were treated with and sodium 
butyrate (2 mM) (SB) (Sigma-Aldrich) or sodium valproate (4 mM) (VPA) (Sigma-Aldrich) for 6- and 24 h (all 
treatments n = 3). VPA is specific for histone deacetylase (HDAC) class I and IIa, whereas SB inhibits HDAC 
class IV alongside class I and  IIa110.
RNA purification cDNA synthesis. RNA from all samples was purified using AllPrep DNA/RNA Mini 
kit (QIAGENgen, Cat. 80204) followed by genomic DNA contamination removal using a DNase kit (Thermo 
Scientific, Cat. EN0525). cDNA was synthesized using Maxima H Minus First Strand cDNA synthesis kit 
(Thermo Scientific, Cat. K1651).
RT‑qPCR. Reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) was performed using an 
AriaMX qPCR machine (Agilent). The following primers were used: Cpt1a (QIAGEN), Cpt1c (QIAGEN), Hprt1 
(5′TGC AGA CTT TGC TTT CCT TGG TCA 3′, 5′-TGG CCT GTA TCC AAC ACT TCGAG3′) All samples were run 
in triplicates. The relative expression of the Cpt1a was calculated according to previously published  methods111.
Statistics. Data was evaluated for normality using Shapiro–wilk test and Q/Q-plots. If normality was present 
unpaired t tests, ordinary one-way ANOVA followed by Tukey’s multiple comparisons post hoc test, ordinary 
two-way ANOVA followed by Sidak’s multiple comparisons post hoc test, or repeated measures (RM) two-way 
ANOVA followed by either Tukey’s, Sidak’s or Bonferroni multiple comparisons post hoc test were used to assess 
statistical significance. If the criteria of normality was not met, a non-parametric Mann–Whitney test was per-
formed. The fold of gene expression was calculated according to previously published  methods111. All statistics 
were performed using Graph Pad Prism software. All data are presented as the mean ± SEM, unless otherwise 
stated. To evaluate possible outliers, a Grubbs test was performed, and outliers were removed. P-values of 0.05 
were considered significant.
Data availability
Data are available upon relevant request to the corresponding author.
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